Search for Clinical Trial Results
Chronic Graft Versus Host Disease - 29 Studies Found
Status | Study |
Completed |
Study Name: Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease Condition: Oral Chronic Graft-versus-host Disease Date: 2008-05-27 Interventions:
|
Withdrawn |
Study Name: Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease Condition: Active Chronic Graft Versus Host Disease Date: 2009-10-26 Interventions: Drug: Pentostatin; Cyclophosphamide; Rituximab Pentostatin 2mg/m2 IV day+1 (up to 6 cycles) Cyclophospha |
Active, not recruiting |
Study Name: Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Condition: Chronic GVHD Date: 2010-04-16 Interventions:
|
Recruiting |
Study Name: Extracorporeal Photopheresis Using Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD) Condition: Refractory Chronic Graft Versus Host Disease (cGVHD) Date: 2015-01-14 Interventions: Device: Photopheresis Theraflex ECP™ The Macopharma (Theraflex ECP™) approach is based on a |
Recruiting |
Study Name: Treatment of Chronic GVHD of Liver or Lungs by ECP Condition: Chronic Graft-Versus Host Disease Date: 2006-01-03 Interventions: Procedure: Extracorporeal photoimmunotherapy |
RECRUITING |
Study Name: A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. Condition: Chronic Graft Versus Host Disease Date: 2024-05-19 Interventions: Pharmaceutical form:Tablet-Route of administration:oral |
RECRUITING |
Study Name: Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease Condition: Chronic Graft Versus Host Disease Date: 2024-05-19 Interventions: Given PO |
NOT_YET_RECRUITING |
Study Name: Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease Condition: Chronic Graft Versus Host Disease Date: 2024-05-19 Interventions: 200mg PO QD x 24 cycles (28-day cycle) |
COMPLETED |
Study Name: Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD) Condition: Chronic Graft Versus Host Disease Date: 2024-05-19 Interventions: The study will follow a standard 3+3 design with two escalating doses of abatacept to determine the maximum tolerated dose (MTD): 3 mg/kg (dose l |